title: [Progress of medical and combined treatment for esophageal carcinoma].
abstract: The combined treatment for esophageal carcinoma evoked increasing attention in clinic. The combination of radiotherapy, chemotherapy and operation is the tendency of combined treatment for esophageal carcinoma. The rational and efficient combined treatment has made more satisfied curative effect than single treatment, which improved the patients' long-term survival rate. Using new chemotherapeutic agents, exploring neoadjuvant chemotherapy, and renewing knowledge of adjuvant chemotherapy are important developments on medical treatment for esophageal carcinoma. This review discussed the progress of medical and combined treatment for esophageal carcinoma from the aspects of curative effect, survival rate, adverse events, and so on.
authors.affiliation: Clinical Cancer Center, Zhongda Hospital, East-south University, Nanjing, Jiangsu 210009, P. R. China. lisuyi@csco.org.cn
authors.forename: Su-Yi
authors.initials: SY
authors.lastname: Li
authors.forename: Xin-Chen
authors.initials: XC
authors.lastname: Sun
authors.forename: Lin
authors.initials: L
authors.lastname: Liu
mesh_terms: D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D004938:Esophageal Neoplasms / Q000188:drug therapy* / Q000601:surgery; D006801:Humans; D020360:Neoadjuvant Therapy; D017239:Paclitaxel / Q000008:administration & dosage; D014747:Vinblastine / Q000008:administration & dosage / Q000031:analogs & derivatives; D000077235:Vinorelbine
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D014747:Vinblastine; D017239:Paclitaxel; D000077235:Vinorelbine